trial

Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F

Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro

Jack Cuzick JACK CUZICK, Wolfson Institute of Preventive Medicine, London New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continu

Jose Baselga JOSE BASELGA, Vall d’Hebron Hospital, Barcelona RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The in

Susan O’Brien SUSAN O’BRIEN, MD Anderson Cancer Center, Houston For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamid

Jonathan Kolitz JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY GEORGE CANELLOS, Dana-Farber Cancer Institute For patients with acute myeloid leukemia in first remission, new data suggests tha

Terry Gernsheimer TERRY GERNSHEIMER, University of Washington Medical Center, Seattle An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chroni

Bengt Eriksson REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta BENGT ERIKSSON, Gothenburg University In a large phase III trial of patients having a h

Gregg Stone REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GREGG STONE, Columbia University, New York New light has been thrown on the u

Ake Hjalmarson Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 AKE HJAL

Gordon Tomaselli Daniel Jones REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GORDON TOMASELLI, Johns Hopkins Universit

Anthony Fung REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida ANTHONY FUNG, University of British Columbia, Vanc

REFERENCE: Abstract: Late Breaking Clinical Trials, Session 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida LESLEE SHAW, Emory University, Atlanta COMMENT: DANI

Jose Baselga Gordon McVie REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona CO

Pedro Cahn REFERENCE: Abstract H-717, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 PEDRO CAHN, Juan A. Fernández Hospital, Buenos Aires Etraviri

JEAN-CLAUDE TARDIF, Montreal Heart Institute REFERENCE: Abstract 405-10, American College of Cardiolgy New Orleans Improvements in atheroma plaque have been achieved by infusing patients who have acut

STEVEN NISSEN, Cleveland Clinic, OH REFERENCE: N Engl J Med 2007 356 Reporting from: American College of Cardiolgy New Orleans Two big studies published in the New England Journal of Medicine and pres

Anthony Wierzbicki Gabriel Steg David Paquette Add HDL-Raising Therapy to Maximise Lipid Treatment REFERENCE: Abstract 53, Page 85 Anthony Wierzbicki, St Thomas’s Hospital, London The idea of ad

Robert Ozols Lawrence Wickerham Patricia Ganz Jorma Paavonen Noah Kauff Robert Ozols of the Fox Chase Cancer Center in Philadelphia joins Derek Thorne to talk about the top presentations on cancer pre

Robert Mayer Thierry Facon Ibrahim Yakoub-Agha Peter Paschka Robert Mayer of the Dana-Farber Cancer Institute in Boston joins Derek Thorne to discuss the major hematologic malignancy news reported at

Dean Bajorin Robert Motzer Gary Hudes Marshall Posner Some major progress in kidney cancer and head and neck cancer was announced at the ASCO meeting in Atlanta, and the Audio Journal of Oncology has

Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with carboplatin in HER-2 positive patients with early breast c

For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin and clopidogrel, according to the ACTIVE-W trial. Stua

Todd McAllister Blood vessels made through tissue engineering are being trialled in humans and may provide a future source of grafts from coronary applications. That is the latest from a California-ba

Frans van der Werf Near-complete data from the ASSENT-4-PCI trial investigating facilitated PCI (combining both thrombolysis and primary PCI after acute myocardial infarction) has found that PCI alone

Edward Romond Edward Romond, University of Kentucky, Lexington More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding

Andrew J Molyneux, Neurovascular Research Unit, Radcliffe Infirmary, Oxford REFERENCE: Lancet 2005;366:809-17 A trans-catheter treatment for ruptured intracranial aneurysm has proved superior to tradi

Keith Fox Keith Fox, Royal Infirmary Edinburgh The RITA-3 trial – focussing on how to manage patients with acute coronary syndromes – reported 5-year data at this year’s ESC Congress

Gilles Montalescot The STEEPLE trial randomised more than 3500 elective angioplasty patients to unfractionated heparin or either of two dose levels of enoxaparin. Gilles Montalescot presented the find